Metronidazol B Infomed Fluids (Metronidazole)

Metronidazole is reduced inside anaerobic cells, forming nitro radicals that damage DNA and inhibit nucleic acid synthesis. This disruption leads to loss of cellular function and death of susceptible bacteria and protozoa, making it effective against a broad range of anaerobic pathogens.

The specific dose and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. Healthcare professionals should follow institutional protocols and adjust as needed.

Safety data are limited; metronidazole should be used in pregnancy only when the potential benefit justifies any potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should consult their healthcare provider before treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic organisms, offering rapid bactericidal activity. Compared with broad‑spectrum agents like clindamycin, it has a narrower spectrum but fewer concerns about Clostridioides difficile overgrowth. Choice depends on pathogen susceptibility, infection site, and patient tolerance.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from direct light, moisture, and extreme temperature fluctuations. Do not freeze the solution, and discard any product that appears discolored or contains particles.

The medication is supplied as a sterile injectable solution for intravenous infusion. It should be administered by a qualified healthcare professional using aseptic technique, typically diluted in compatible IV fluids and infused over the period recommended by the prescriber.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, and rare skin disorders like Stevens‑Johnson syndrome. Patients should be monitored for neurological symptoms, skin changes, or signs of hypersensitivity, and therapy should be discontinued if these occur.

Metronidazole is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazoles. Caution is also advised for individuals with severe hepatic impairment, those receiving concurrent disulfiram therapy, and patients with a history of severe neurologic reactions to the drug.